Abstract 1261: A next generation tri-complex KRASG12C(ON) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRASG12C(OFF) inhibition

癌症研究 药理学 生物
作者
R. Jeremy Nichols,Jim Cregg,Christopher J. Schulze,Zhican Wang,Kevin Yang,Jingjing Jiang,Daniel M. Whalen,Rich Hansen,Lindsay S. Garrenton,Alun Bermingham,John E. Knox,Tiffany J. Choy,Denise F. Reyes,Mayra Rios,Kyle J. Seamon,Michael Longhi,Kang-Jye Chou,Shaoling Li,David Wildes,Mallika Singh,Elena S. Koltun,Adrian L. Gill,Jacqueline A.M. Smith
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:81 (13_Supplement): 1261-1261 被引量:8
标识
DOI:10.1158/1538-7445.am2021-1261
摘要

Abstract The KRASG12C mutation is found in 11% of non-small cell lung cancers and 4% of colorectal cancers. Recently, a class of KRASG12C(OFF) inhibitors has shown promising activity in patients whose cancers bear KRASG12C. These data validate KRASG12C as an oncogenic driver, as well the mechanism of action of the KRASG12C(OFF) inhibitor class – sequestration of inactive, GDP-bound KRASG12C(OFF) proteins. Previous work has demonstrated this mechanism of action is vulnerable to adaptive tumor cell responses that activate KRASG12C by increasing upstream signaling and driving the cellular pool of KRASG12C towards the RAS(ON) state. These escape mechanisms, in which KRASG12C can be reactivated in the presence of a KRASG12C(OFF) inhibitor, highlight the potential for an inhibitor that directly targets and disables the KRASG12C(ON) form. Using structure-based drug design, we have discovered RM-032, a potent covalent inhibitor of KRASG12C(ON) that forms a tri-complex between KRASG12C(ON) and cyclophilin A (CypA), a highly abundant immunophilin. The assembled tri-complex prevents KRASG12C(ON) from signaling via steric blockade of RAS effector binding. In cells, kinetic analyses demonstrate near-immediate disruption of RAS effector binding and extinction of KRASG12C(ON) signaling. RM-032 is dual selective for KRASG12C(ON) and NRASG12C(ON). In vitro, RM-032 drives increased durability of inhibition of both RAS pathway signaling and cell proliferation in KRASG12C tumor cells compared with KRASG12C(OFF) inhibition. RM-032 displays attractive drug-like properties including cross-species oral bioavailability, and is predicted to achieve adequate exposures following oral dosing in humans. Oral administration of RM-032 produces deep and durable suppression of RAS pathway activity in KRASG12C tumor models and drives profound tumor regressions in vivo at well-tolerated doses. Across multiple tumor xenograft models, advanced KRASG12C(ON) inhibitors, including RM-032, appear to outperform KRASG12C(OFF) inhibitors. RM-032 permits a broad array of combination opportunities for treating KRASG12C mutant cancer types where single agent KRASG12C(ON) inhibition may be insufficient, for example with agents targeting nodes both upstream (e.g., SHP2 and SOS1) and downstream (e.g., MEK and ERK) of RAS, as well as parallel pathways (e.g., mTORC1). RM-032 is a next generation mutant-selective inhibitor of KRASG12C(ON) that may overcome liabilities of first-generation KRASG12C(OFF) inhibitors and provide additional benefit to patients by directly targeting the active form of this important oncogenic driver mutation. Citation Format: Robert J. Nichols, Jim Cregg, Christopher J. Schulze, Zhican Wang, Kevin Yang, Jingjing Jiang, Daniel M. Whalen, Rich Hansen, Lindsay S. Garrenton, Alun Bermingham, John E. Knox, Tiffany Choy, Denise Reyes, Mayra Rios, Kyle Seamon, Michael Longhi, Kang-Jye Chou, Shaoling Li, David P. Wildes, Mallika Singh, Elena S. Koltun, Adrian L. Gill, Jacqueline A. M. Smith. A next generation tri-complex KRASG12C(ON) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRASG12C(OFF) inhibition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1261.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
littlebenk完成签到,获得积分10
刚刚
lulu完成签到,获得积分10
1秒前
1秒前
Maestro_S的应助被NAN采纳,获得10
1秒前
2秒前
2秒前
一般路过发布了新的文献求助10
3秒前
Steady完成签到 ,获得积分10
4秒前
111发布了新的文献求助10
4秒前
小羊完成签到,获得积分10
4秒前
4秒前
sh完成签到,获得积分10
5秒前
5秒前
忧心的映真完成签到,获得积分10
5秒前
5秒前
平淡如天完成签到,获得积分10
6秒前
1111发布了新的文献求助10
6秒前
冷酷行恶完成签到 ,获得积分10
6秒前
cherry发布了新的文献求助10
6秒前
霁星河发布了新的文献求助20
6秒前
Liu完成签到,获得积分10
6秒前
6秒前
7秒前
小马甲的应助被hu采纳,获得10
7秒前
菜籽发布了新的文献求助10
7秒前
8秒前
每日早睡完成签到 ,获得积分10
8秒前
8秒前
时平谊完成签到,获得积分20
8秒前
ly的应助被李垚采纳,获得10
9秒前
YYT发布了新的文献求助10
9秒前
所所的应助被ZND采纳,获得10
9秒前
9秒前
华仔的应助被哈哈采纳,获得10
9秒前
能不能给我来篇SSCI完成签到,获得积分10
11秒前
乐空思的应助被Ken采纳,获得30
11秒前
研友_8WbVOZ发布了新的文献求助30
12秒前
Rc晨光发布了新的文献求助10
12秒前
深情安青的应助被细草微风岸采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593